A Placebo-Controlled Trial of Prucalopride for Severe Chronic Constipation
Open accessThe DOI matches its Crossref record; 35 of the 36 references it cites were found in a registry or an index.
Abstract
BACKGROUND: In this 12-week trial, we aimed to determine the efficacy of prucalopride, a selective, high-affinity 5-hydroxytryptamine4 receptor agonist, in patients with severe chronic constipation. METHODS: In our multicenter, randomized, placebo-controlled, parallel-group, phase 3 trial, patients with severe chronic constipation (< or =2 spontaneous, complete bowel movements per week) received placebo or 2 or 4 mg of prucalopride, once daily, for 12 weeks. The primary efficacy end point was the proportion of patients having three or more spontaneous, complete bowel movements per week, averaged over 12 weeks. Secondary efficacy end points were derived from daily diaries and validated questionnaires completed by patients. Adverse events, clinical laboratory values, and cardiovascular effects were monitored. RESULTS: Efficacy was analyzed in 620 patients. The proportion of patients with three or more spontaneous, complete bowel movements per week was 30.9% of those receiving 2 mg of prucalopride and 28.4% of those receiving 4 mg of prucalopride, as compared with 12.0% in the placebo group (P<0.001 for both comparisons). Over 12 weeks, 47.3% of patients receiving 2 mg of prucalopride and 46.6% of those receiving 4 mg of prucalopride had an increase in the number of spontaneous, complete bowel movements of one or more per week, on average, as compared with 25.8% in the placebo group (P<0.001 for both comparisons). All other secondary efficacy end points, including patients' satisfaction with their bowel function and treatment and their perception of the severity of their constipation symptoms, were significantly improved with the use of 2 or 4 mg of prucalopride as compared with placebo, at week 12. The most frequent treatment-related adverse events were headache and abdominal pain. There were no significant cardiovascular effects of treatment. CONCLUSIONS: Over 12 weeks, prucalopride significantly improved bowel function and reduced the severity of symptoms in patients with severe chronic constipation. Larger and longer trials are required to further assess the risks and benefits of the use of prucalopride for chronic constipation. (ClinicalTrials.gov number, NCT00483886 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Five 12-week randomized double-blinded placebo-controlled trials evaluated the use of prucalopride (2 mg daily) for the management of CIC. 75-79”
Citations
Cites
Jaeschke, R., Singer, J., & Guyatt, G. H. (1989) · Controlled Clinical Trials · doi:10.1016/0197-2456(89)90005-6 · Cited by 4,982
(1994) · Medical Entomology and Zoology · Cited by 4,156
Epidemiology of Constipation in North America: A Systematic Review
Higgins, P. D., & Johanson, J. F. (2004) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2004.04114.x · Cited by 1,080
Prolonged QTc Interval and Risk of Sudden Cardiac Death in a Population of Older Adults
Straus, S. M. J. M., Kors, J. A., De Bruin, M. L., van der Hooft, C. S., Hofman, A., Heeringa, J., Deckers, J. W., Kingma, J. H., Sturkenboom, M. C. J. M., Stricker, B. H. C., et al. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.08.067 · Cited by 833
Lembo, A., & Camilleri, M. (2003) · New England Journal of Medicine · doi:10.1056/nejmra020995 · Cited by 692
Self-citationChronic constipation: a survey of the patient perspective
JOHANSON, J. F., & KRALSTEIN, J. (2007) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2006.03238.x · Cited by 617
Development and validation of the Patient Assessment of Constipation Quality of Life questionnaire
Marquis, P., De La Loge, C., Dubois, D., McDermott, A., & Chassany, O. (2005) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365520510012208 · Cited by 584
Stewart, W. (1999) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(99)00701-7 · Cited by 492
Psychometric Validation of a Constipation Symptom Assessment Questionnaire
L. Frank, L. K. (1999) · Scandinavian Journal of Gastroenterology · doi:10.1080/003655299750025327 · Cited by 458
The Health-Related Quality of Life and Economic Burden of Constipation
Dennison, C., Prasad, M., Lloyd, A., Bhattacharyya, S. K., Dhawan, R., & Coyne, K. (2005) · PharmacoEconomics · doi:10.2165/00019053-200523050-00006 · Cited by 396
Research works printed but not linked: 3
- 10.1111/j.1572-0241.1999.01642.x · doi:10.1111/j.1572-0241.1999.01642.x · Paper page
- 10.1111/j.1572-0241.2002.05843.x · doi:10.1111/j.1572-0241.2002.05843.x · Paper page
- Schiller LR, 2004, Rev Gastroenterol Disord, 4, S43
Cited by
Items 501–581 of 581
Dexloxiglumide for the treatment of constipation predominant irritable bowel syndrome
Serra, J., & Caballero, N. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1229306 · Cited by 1
Current Status of Translational Research on Constipation
Lee, H. J., & Park, K. S. (2016) · Korean Journal of Gastroenterology · doi:10.4166/kjg.2016.68.3.143
Magen-Darm-Mittel und Lebertherapeutika
Schwabe, U., & Paffrath, D. (2014)
Approach to Patients with Refractory Constipation
Gwee, K., Gong, X., & Siah, K. T. H. (2016) · Springer eBooks · doi:10.1007/978-81-322-0822-8_7
Droney, J. (2012) · Spiral (Imperial College London) · doi:10.25560/9252 · Cited by 1
Pharmacological and Clinical Treatment of Irritable Bowel Syndrome
Sałaga, M., & Mosińska, P. (2016) · Springer eBooks · doi:10.1007/978-3-319-49016-8_4
Moderne Therapie der Obstipation
Menge, D., Layer, P., & Andresen, V. (2017) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/s-0042-116460
“Z Gastroenterol 2013; 51: 651–672 [2] Camilleri M, Kerstens R, Rykx A et al.”
BackgroundThe Pharmacological Management of Chronic Constipation and Faecal Incontinence
Kamperidis, N., & Arebi, N. (2016) · Springer eBooks · doi:10.1007/978-3-319-43214-4_11
Therapieoptionen bei Obstipation und Diarrhö
Sj, L. (2010)
Targeting cyclic GMP signaling for the treatment of gastrointestinal diseases
Sharman, S. K. (2017) · Scholarly Commons @Augusta University
Comment prescrire les nouveaux traitements de la constipation et pour qui ?
Vitton, V. (2018) · Côlon & Rectum · doi:10.3166/s11725-017-0758-3
TREATMENT OF IRRITABLE BOWEL SYNDROME: A REVIEW
Bikash, G., Dash, B., Sujata, P., & Bora, A. J. (2018) · Asian Journal of Pharmaceutical and Clinical Research · doi:10.22159/ajpcr.2018.v11i9.25953
Constipation and Dyssynergic Defecation
Mion, F. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-815346-8.00017-5
Picard, E. (2017) · theses.fr (ABES) · doi:10.70675/a097cb67zaf8ez40a3z8ab8z44bb8a400b3a
Ping, Y. I. N., Gao, N., Bo, D. O. N. G., Zheng, H., Chen, Z., Yin, X., Wu, J., Cao, Y. H., & Xu, S. (2019) · 世界针灸杂志:英文版 · doi:10.1016/j.wjam.2019.05.001 · Cited by 2
Am, P. (2019) · Biomedical Journal of Scientific & Technical Research · doi:10.26717/bjstr.2019.19.003312
“In the esophagus and stomach, serotonin is present in the neurons of the enteric nervous system and extraorgan serotonergic neurons and fibers [1-4], which regulate the motor function of these organs.”
Background(2017) · Elsevier eBooks · doi:10.1016/b978-3-437-23316-6.00004-5
ERKRANKUNGEN DER VERDAUUNGSORGANE
Jung, N., Mayet, W.-J., Mertens, P. R., (federführend), J. M., Müller, O.-A., Pfeifer, M., Schellinger, P. D., Weiss, N., & Wendtner, C. (2020) · Elsevier eBooks · doi:10.1016/b978-3-437-06282-7.50008-5
O efeito da prucaloprida na atividade motora do esôfago em pessoas assintomáticas
Kahwage, R. L. (2020) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.17.2020.tde-13042020-151241
Management Diarrhea in Systemic Sclerosis
Volkmann, E. R. (2020) · In clinical practice · doi:10.1007/978-3-030-53736-4_17
Pharmacological Treatments for Constipation and Opioid-Induced Constipation
Camilleri, M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00009-8
Self-citationResponse to Philips and Abraham
Sun, Y., & Liu, Z. (2021) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000001383
Gastrointestinal Complications of Neuromuscular Disorders
Ismail, M. K., & Shrestha, S. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-71317-7.00004-4
(2012) · Côlon & Rectum · doi:10.1007/s11725-012-0430-x
Ommer, A., Hetzer, F. H., Krammer, H., & Shafik, A. (2018) · Springer eBooks · doi:10.1007/978-3-662-54682-6_9
Dharmarajan, T. S., Widjaja, D., & Pitchumoni, C. S. (2020) · Springer eBooks · doi:10.1007/978-3-319-90761-1_45-1
Dharmarajan, T. S., Dharmarajan, T. S., Dharmarajan, T. S., Dharmarajan, T. S., Widjaja, D., Pitchumoni, C. S., Pitchumoni, C. S., & Pitchumoni, C. S. (2012) · Springer eBooks · doi:10.1007/978-1-4419-1623-5_34
(2009) · Current Opinion in Oncology · doi:10.1097/cco.0b013e32832e
Gysling, E. (2012) · pharma-kritik · doi:10.37667/pk.2011.865
Piche, T. (2011) · Springer eBooks · doi:10.1007/978-2-8178-0237-4_9
Prucalopride: a guide to its use in chronic constipation
&NA; (2010) · Drugs & Therapy Perspectives · doi:10.2165/11205150-000000000-00000
Daeninck, P. J., & Hiebert, T. (2012) · Oxford University Press eBooks · doi:10.1093/acprof:oso/9780199694143.003.0062
Trastornos funcionales y motores digestivos
Mearin, F., Juan, A. P., & Balboa, A. (2008) · Gastroenterología y Hepatología · doi:10.1016/s0210-5705(08)76624-x
Magen-Darm-Mittel und Laxantien
Mössner, J. (2012) · Springer eBooks · doi:10.1007/978-3-642-29242-2_32
Laxatives and Other Drugs for Constipation
Canning, S. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.65642-8
Marušić, M., Perić, R. T., & Karaula, N. T. (2018) · Clinical gastroenterology · doi:10.1007/978-3-319-75856-5_15
(2008) · British journal of surgery · doi:10.1002/bjs.6469
Waha, J. E., & Pfeifer, J. (2020) · Springer eBooks · doi:10.1007/978-3-030-43811-1_18
Ali-Ross, N., & Smith, A. R. B. (2010) · CRC Press eBooks · doi:10.3109/9781439807217-61
Magen-Darm-Mittel und Lebertherapeutika
Lohse, A. W., & Mössner, J. (2019) · Springer eBooks · doi:10.1007/978-3-662-59046-1_34
Funktionelle Magen-Darm-Erkrankungen
Keller, J., & Layer, P. (2014) · Humanmedizin kompakt · doi:10.1007/s40355-014-0024-y
Magen-Darm-Mittel und Lebertherapeutika
Lohse, A. W., & Huber, S. (2020) · Springer eBooks · doi:10.1007/978-3-662-62168-4_31
Magen-Darm-Mittel und Lebertherapeutika
Mössner, J. (2016) · Springer eBooks · doi:10.1007/978-3-662-50351-5_33
Keller, J., & Layer, P. (2014) · Springer eBooks · doi:10.1007/978-3-642-54676-1_329-1
Constipation and Fecal Incontinence in the Elderly
Richter, B. I., Skryd, A. F., & Smukalla, S. M. (2022) · Current Treatment Options in Gastroenterology · doi:10.1007/s11938-022-00401-1
CONSTIPATION (REPORT 2: TREATMENT) (literature review)
Платошкин, Э. Н., & Шут, С. А. (2014) · Health and Ecology Issues · doi:10.51523/2708-6011.2014-11-2-4
Deutsche Gesellschaft für Experimentelle und Klinische Pharmakologie und Toxikologie e.V.
(2012) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-012-0736-0
Chronic intestinal pseudo-obstruction
Gonzalez, Z., Stanghellini, V., & GIORGIO, R. D. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-13911-6.00017-7
Pediatric and adolescent GI motility disorders and management
Lu, P. L., Bali, N., & Lorenzo, C. D. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-13911-6.00030-x · Cited by 1
Review on Recent Advancements in the Treatment of Irritable Bowel Syndrome (IBS)
-, P. S. G., Jawarkar, S. G., & Bobade, N. N. (2023) · International Journal For Multidisciplinary Research · doi:10.36948/ijfmr.2023.v05i06.9601
Rahatullah, H. S. (2024) · International Journal of Current Science Research and Review · doi:10.47191/ijcsrr/v7-i6-29
“Prucalopride, a highly selective 5-HT4 receptor agonist, has not been evaluated in IBS patients but has shown effectiveness in chronic idiopathic constipation, serving as a viable therapeutic option when laxatives fail (Camilleri, Kerstens, Rykx, & Vandeplassche, 2008; Tack et al., 2012).”
BackgroundAdvances in the Treatment of Intestinal Dysfunction after Lumbar Fusion Surgery
张, 云. (2024) · Advances in Clinical Medicine · doi:10.12677/acm.2024.1482237
Perić, R. T., Karaula, N. T., Madunić, M., & Soldo, A. M. (2024) · Clinical gastroenterology · doi:10.1007/978-3-031-69800-2_6 · Cited by 1
Mohamed, A. R., Sayed, R. A., Shalaby, A., & Ibrahim, H. (2025) · Scientific Reports · doi:10.1038/s41598-024-85001-y
Huang, X., Wang, Y., Li, B., Shen, X., Tao, X., Zheng, W., Luo, Q., Xiong, L., Wang, L., & Cai, S. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1562692
Ommer, A., & Krammer, H. (2025) · Springer eBooks · doi:10.1007/978-3-662-68510-5_14
Exploring Approaches to Addressing Gastrointestinal Disorders in Patients with Anxiety
Volodikhina, A. A., Akhmedova, A. R., Uzdenov, M. B., Dzhabrailova, M. L., Voytleva, R. K., & Achilov, V. I. (2021) · International Journal of Social and Psychological Aspects of Healthcare · doi:10.51847/xhaa49ruml
Gao, S., Zhu, L., Yao, H., Fang, J., & Liu, Z. (2025) · Integrative Medicine Research · doi:10.1016/j.imr.2025.101253
“13,14,16,32 Accordingly, we adopted the non-inferiority margin of (cid:0) 0.53, approximately one-half of the between-group difference.”
InfluentialChronic Obstipation: pharmacological treatment in adults
Antunes, S. M. M. (2023) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · doi:10.34626/rt9x-q823
Obstipação crónica no idoso : opções terapêuticas
Couto, J. R. D. S. (2014) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · Cited by 2
Gastrointestinal Drugs in Scleroderma and GI Dysmotility
Shah, D., Ayer, D., Chuy, D. S., Almahmoud, S., Akhtar, K., Farrell, J., & Tadros, M. S. (2025) · Clinical gastroenterology · doi:10.1007/978-3-032-07868-1_18
Brenner, D. M., Moshiree, B., de Courcy, J., Reynolds, N. A., Taylor-Whiteley, T., Jiang, J., Lu, M., Terreri, B., & Shah, E. D. (2026) · Gastro Hep Advances · doi:10.1016/j.gastha.2026.100900
Design of Treatment Trials for Disorders of Gut–Brain Interaction
Sayuk, G. S., Brenner, D. M., Carbone, F., Knowles, S. R., Lacy, B. E., Staudacher, H. M., & Ford, A. C. (2026) · Gastroenterology · doi:10.1053/j.gastro.2025.12.040 · Cited by 2
Zhao, L., Sun, X., Zhu, L., Chen, B., Qin, D., Fang, S., Gao, J., Liu, C., Wu, H., Liu, F., et al. (2026) · Phytomedicine · doi:10.1016/j.phymed.2026.157991
Rajindrajith, S., Hathagoda, W., Balakrishnan, K., & Devanarayana, N. M. (2026) · World Journal of Clinical Pediatrics · doi:10.5409/wjcp.v15.i1.113925
Maurel, S. (2024) · theses.fr (ABES) · doi:10.70675/f3a2932cz273fz47adzb18cz58f50bf2e53d · Cited by 2
Ishihara, Y., Ihara, E., Ohkubo, H., Ohira, M., Tomita, N., Takahashi, K., Oyamada, S., Kurihashi, T., Iwasaki, T., Usuda, H., et al. (2026) · Clinical and Translational Gastroenterology · doi:10.14309/ctg.0000000000001046
“1 point for the satisfaction domain, according to previous studies (22,23).”
Diagnosis and treatment of slow-transit constipation
Yang, F., & Tao, Q. (2026) · BMC Gastroenterology · doi:10.1186/s12876-026-04784-8
“The most common side effects reported were headache, nausea, and diarrhea [63].”
Development of Personal Formulary for Constipation in Tertiary Care Settings
Pandit, P., Kumar, R. K., Nishi, Roy, S. S., & Mohan, L. (2026) · International Journal of Science and Healthcare Research · doi:10.52403/ijshr.20260217
Management of constipation: A narrative review of evolving strategies and methodological challenges
Goyal, M. K., Brahmandam, G., Chowdhary, R., guna, S. D. S., Shah, D., Goyal, P., Vuthaluru, A. R., & Goyal, O. (2026) · World Journal of Methodology · doi:10.5662/wjm.118399
Shang, A., Yan, S., Chenghao, 李. L., Wu, Y., Tian, N., Pan, S., Liu, H., Yang, D., & Wang, J. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c02509
Bush, J., Iwuamadi, I., & Deehan, E. C. (2026) · Nutrients · doi:10.3390/nu18213538
Funktionelle Magen-Darm-Erkrankungen
Keller, J., & Layer, P. (2014) · coloproctology · doi:10.1007/s00053-014-0440-2
Obstructed Defecation Syndrome
Gorissen, K. J., & Gosselink, M. P. (2013) · Updates in surgery/Updates in surgery series · doi:10.1007/978-88-470-5441-7_9
Metadata
- Authors
- Camilleri, M., Kerstens, R., Rykx, A., & Vandeplassche, L.
- Affiliations
- Mayo Clinic (US)
- ORCID
- Camilleri, Michael
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2008-05-29
- Volume
- 358
- Issue
- 22
- Pages
- 2344-2354
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2068454300
- Cited by
- 576
- References
- 36
- Citations by year
- 2026: 13 · 2025: 16 · 2024: 18 · 2023: 19 · 2022: 16 · 2021: 28 · 2020: 28 · 2019: 19 · 2018: 29 · 2017: 33 · 2016: 38 · 2015: 33 · 2014: 46 · 2013: 50 · 2012: 49
- FWCI
- 45.65
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Health Sciences › Medicine › Urology › Pelvic floor disorders treatments
- Health Sciences › Medicine › Surgery › Congenital gastrointestinal and neural anomalies
- Keywords
- prucalopride, serotonin receptor agonists, 5-HT4 receptor agonist, stool frequency, treatment-related adverse events, cardiovascular safety
- MeSH terms
- Adolescent, Adult, Aged, Aged, 80 and over, Benzofurans, Chronic Disease, Constipation, Defecation, Double-Blind Method, Electrocardiography, Female, Humans, Male, Middle Aged, Quality of Life, Surveys and Questionnaires, Serotonin Receptor Agonists, Laxatives, Serotonin 5-HT4 Receptor Agonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.